Erratum: Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression (Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression (2017) 19(6) (1189–1201), (S2211124717305259), (10.1016/j.celrep.2017.04.031));Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Cell Reports

Volumn 19, Issue 6, 2017, Pages 1189-1201

  Garcia Diaz, Angel ^a   Shin, Daniel Sanghoon ^a   Moreno, Blanca Homet ^a,b   Saco, Justin ^a   Escuin Ordinas, Helena ^a   Rodriguez, Gabriel Abril ^a   Zaretsky, Jesse M ^a   Sun, Lu ^c   Hugo, Willy ^c   Wang, Xiaoyan ^c   Parisi, Giulia ^a   Saus, Cristina Puig ^a   Torrejon, Davis Y ^a   Graeber, Thomas G ^a,c   Comin Anduix, Begonya ^a,c   Hu Lieskovan, Siwen ^a   Damoiseaux, Robert ^a,c   Lo, Roger S ^a,c   Ribas, Antoni ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

immunotherapy; interferon receptor signaling pathways; IRF1; JAK STATs; melanoma; PD 1; PD L1; PD L2

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 1; JANUS KINASE 1; JANUS KINASE 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; SHORT HAIRPIN RNA; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; CD274 PROTEIN, HUMAN; IRF1 PROTEIN, HUMAN; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROTEIN BINDING; STAT PROTEIN;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

B7-H1 ANTIGEN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-BETA; INTERFERON-GAMMA; JANUS KINASE 1; JANUS KINASE 2; MELANOMA; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 85019192700     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2019.11.113     Document Type: Erratum

References (48)

1. Aaronson, D.S., Horvath, C.M., A road map for those who don't know JAK-STAT. Science 296 (2002), 1653–1655.
2. Atefi, M., Avramis, E., Lassen, A., Wong, D.J., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T.G., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 20 (2014), 3446–3457.
3. Chen, X., Prywes, R., Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression. Mol. Cell. Biol. 19 (1999), 4695–4702.
4. Darnell, J.E. Jr., Kerr, I.M., Stark, G.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994), 1415–1421.
5. Decker, T., Lew, D.J., Mirkovitch, J., Darnell, J.E. Jr., Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor. EMBO J. 10 (1991), 927–932.
6. Domanski, P., Colamonici, O.R., The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 7 (1996), 143–151.
7. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
8. Dunn, G.P., Sheehan, K.C.F., Old, L.J., Schreiber, R.D., IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65 (2005), 3447–3453.
9. Escuin-Ordinas, H., Atefi, M., Fu, Y., Cass, A., Ng, C., Huang, R.R., Yashar, S., Comin-Anduix, B., Avramis, E., Cochran, A.J., et al. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol. Oncol. 8 (2014), 250–260.
10. Friedman, R.L., Stark, G.R., α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 314 (1985), 637–639.
11. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167 (2016), 397–404.
12. Herbst, R.S., Soria, J.-C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
13. Isaacs, A., Lindenmann, J., Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147 (1957), 258–267.
14. Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14 (2014), 36–49.
15. Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., Schreiber, R.D., Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95 (1998), 7556–7561.
16. Kappes, J.C., Wu, X., Safety considerations in vector development. Somat. Cell Mol. Genet. 26 (2001), 147–158.
17. Kessler, D.S., Levy, D.E., Darnell, J.E. Jr., Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. Proc. Natl. Acad. Sci. USA 85 (1988), 8521–8525.
18. Kim, J., Myers, A.C., Chen, L., Pardoll, D.M., Truong-Tran, Q.-A., Lane, A.P., McDyer, J.F., Fortuno, L., Schleimer, R.P., Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 33 (2005), 280–289.
19. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., Salzberg, S.L., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol., 14, 2013, R36.
20. König, R., Chiang, C.Y., Tu, B.P., Yan, S.F., DeJesus, P.D., Romero, A., Bergauer, T., Orth, A., Krueger, U., Zhou, Y., Chanda, S.K., A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4 (2007), 847–849.
21. Kutmon, M., van Iersel, M.P., Bohler, A., Kelder, T., Nunes, N., Pico, A.R., Evelo, C.T., PathVisio 3: an extendable pathway analysis toolbox. PLoS Comput. Biol., 11, 2015, e1004085.
22. Kutmon, M., Riutta, A., Nunes, N., Hanspers, K., Willighagen, E.L., Bohler, A., Mélius, J., Waagmeester, A., Sinha, S.R., Miller, R., et al. WikiPathways: capturing the full diversity of pathway knowledge. Nucleic Acids Res. 44:D1 (2016), D488–D494.
23. Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., Choi, I.H., Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 580 (2006), 755–762.
24. Lew, D.J., Decker, T., Strehlow, I., Darnell, J.E., Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons. Mol. Cell. Biol. 11 (1991), 182–191.
25. Loke, P., Allison, J.P., PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100 (2003), 5336–5341.
26. Marzec, M., Zhang, Q., Goradia, A., Raghunath, P.N., Liu, X., Paessler, M., Wang, H.Y., Wysocka, M., Cheng, M., Ruggeri, B.A., Wasik, M.A., Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. USA 105 (2008), 20852–20857.
27. Novick, D., Cohen, B., Rubinstein, M., The human interferon α/β receptor: characterization and molecular cloning. Cell 77 (1994), 391–400.
28. Pachkov, M., Erb, I., Molina, N., van Nimwegen, E., SwissRegulon: a database of genome-wide annotations of regulatory sites. Nucleic Acids Res. 35 (2007), D127–D131.
29. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
30. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005), 375–386.
31. Platanias, L.C., Uddin, S., Bruno, E., Korkmaz, M., Ahmad, S., Alsayed, Y., Van Den Berg, D., Druker, B.J., Wickrema, A., Hoffman, R., CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp. Hematol. 27 (1999), 1315–1321.
32. Qing, Y., Stark, G.R., Alternative activation of STAT1 and STAT3 in response to interferon-γ. J. Biol. Chem. 279 (2004), 41679–41685.
33. Ribas, A., Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5 (2015), 915–919.
34. Saha, B., Jyothi Prasanna, S., Chandrasekar, B., Nandi, D., Gene modulation and immunoregulatory roles of interferon γ. Cytokine 50 (2010), 1–14.
35. Sambrook, J., Fritsch, E.F., Maniatis, T., Molecular cloning: a laboratory manual. 1989, Cold spring harbor laboratory press.
36. Schroder, K., Hertzog, P.J., Ravasi, T., Hume, D.A., Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75 (2004), 163–189.
37. Shin, D., Garcia-Diaz, A., Zaretsky, J., Escuin-Ordinas, H., Hu-Lieskovan, S., Palaskas, N.J., Hugo, W., Komenan, M.S., Chmielowski, B., Cherry, G., et al. Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure. J. Immunother. Cancer, 3, 2015, 311.
38. Shin, D.S., Zaretsky, J.M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C.S., Hugo, W., Sandoval, S., Torrejon, D.Y., et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7 (2017), 188–201.
39. Silva, J.M., Li, M.Z., Chang, K., Ge, W., Golding, M.C., Rickles, R.J., Siolas, D., Hu, G., Paddison, P.J., Schlabach, M.R., et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37 (2005), 1281–1288.
40. Smith, P.L., Lombardi, G., Foster, G.R., Type I interferons and the innate immune response–more than just antiviral cytokines. Mol. Immunol. 42 (2005), 869–877.
41. Sriuranpong, V., Park, J.I., Amornphimoltham, P., Patel, V., Nelkin, B.D., Gutkind, J.S., Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 63 (2003), 2948–2956.
42. Stefan, M., Jacobson, E.M., Huber, A.K., Greenberg, D.A., Li, C.W., Skrabanek, L., Conception, E., Fadlalla, M., Ho, K., Tomer, Y., Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon α-modulated mechanism. J. Biol. Chem. 286 (2011), 31168–31179.
43. Stump, K.L., Lu, L.D., Dobrzanski, P., Serdikoff, C., Gingrich, D.E., Dugan, B.J., Angeles, T.S., Albom, M.S., Ator, M.A., Dorsey, B.D., et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res. Ther., 13, 2011, R68.
44. Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J.E., Pai, S.I., Shalabi, A., Shin, T., Pardoll, D.M., Tsuchiya, H., B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193 (2001), 839–846.
45. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
46. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman, F., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3, 2002, H0034.
47. Velazquez, L., Fellous, M., Stark, G.R., Pellegrini, S., A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70 (1992), 313–322.
48. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.